Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015074 | 0.92 | TDP1 (0.68) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL23014817 | 0.87 | TDP1 (0.65) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL135032 | 0.86 | TDP1 (1.00) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| Bromide SCHEMBL15822430 | 0.84 | TDP1 (0.96) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL6115248 | 0.84 | TDP1 (0.96) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL6114843 | 0.84 | TDP1 (0.96) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL25380936 | 0.84 | TDP1 (0.96) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL25381701 | 0.84 | TDP1 (0.96) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL6114977 | 0.84 | TDP1 (0.96) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL25381172 | 0.84 | TDP1 (0.96) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022040-A1 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010065110-A2 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022040-A1 | ANTIMICROBIALS | PAM, MPO, OXA1L | L3MBTL1 2171/4885TDP1 4592/4885HRH1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.